Case Study: GLP-1 Medication Research Study
Tekton met enrollment goals for a GLP-1 study in Moore, OK three months early, with a one-day regulatory turnaround.
Case Studies
Case Study: Phase 2 Migraine Research Study
Tekton delivered a Phase 2 migraine study in Yukon, OK with 100% patient retention and a 1.5-day regulatory turnaround.
Case Study: Achieving 120% of Enrollment Targets for a Teen Cytomegalovirus (CMV) Trial at 5 Sites
Tekton achieved an average of 172% enrollment across three sites, enrolling more than 30 patients in a recent Type 1 Diabetes clinical trial.
Case Study: Advancing Glucose Monitoring for Pregnant Women with Diabetes
Tekton reached 240% of enrollment goals, enrolling 12 patients in a CGM study for pregnant women with diabetes.
Study Performance: Achieving 172% of Enrollment Targets for a Type 1 Diabetes Trial at 3 Sites
Tekton averaged 172% enrollment across three sites, enrolling 30+ patients in a Type 1 Diabetes clinical trial.
Study Performance: Accelerating Alzheimer’s Disease Research
Tekton Research averaged a one-day turnaround from site activation to first patient visit across seven sites in a recent Phase 3 norovirus vaccine trial.
Case Study: Fast-Tracking Enrollment for a Global Phase 3 Norovirus Vaccine Trial
Tekton Research achieved an average of one day from site activation to first patient visit across seven sites in a Phase 3 norovirus vaccine trial.
Case Study: Achieving 172% of Enrollment Targets for a Global Phase 3 Trial
Tekton achieved an average of 172% enrollment across seven sites, enrolling more than 720 patients in a 2024 Global Phase 3 vaccine clinical trial.